Product
Netarsudil/Latanoprost
1 clinical trial
1 indication
Indication
GlaucomaClinical trial
A Multicenter, Open-Label Rocklatan® (Netarsudil/Latanoprost Ophthalmic Solution) 0.02%/0.005% Evaluation of IOP Lowering Efficacy and Safety as Replacement of Current Medical Therapy Regimen for the Reduction of Elevated Intraocular Pressure in Patients With Glaucoma or Ocular HypertensionStatus: Completed, Estimated PCD: 2023-03-22